Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on Coherus Biosciences and keeping the price target at $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Coherus Biosciences’ promising growth trajectory and strategic positioning. The company has shown significant growth momentum with its drug Loqtorzi, particularly in the treatment of advanced nasopharyngeal carcinoma (NPC). The drug’s inclusion in the NCCN guidelines as a preferred regimen has led to increased adoption in academic centers, and the company is strategically targeting the community setting, where a majority of NPC patients are treated, to further drive growth.
Additionally, Coherus is well-positioned to capitalize on the $150M-$200M market potential of Loqtorzi in NPC, especially after restructuring efforts. The company’s pipeline, including assets like casdozo, shows promising potential, with positive early data suggesting efficacy in hepatocellular carcinoma (HCC). This could lead to expanded indications for Loqtorzi and open up new business development opportunities in the U.S. Overall, these factors contribute to a positive outlook for Coherus, justifying the Buy rating.
Tsao covers the Healthcare sector, focusing on stocks such as Argenx Se, Crinetics Pharmaceuticals, and Protagonist Therapeutics. According to TipRanks, Tsao has an average return of 10.8% and a 44.96% success rate on recommended stocks.